Ophthalmology - Page 2
The MD Magazine Ophthalmology - Page 2 specialty page provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.

Sponsored

The 10 Best Health Stories from December
The MD Magazine editors rounded up the 10 best stories from December—did you read them all?
Some cases of tubulointerstitial nephritis and uveitis syndrome, or TINU, have a poor visual prognosis, so early diagnosis and treatment are recommended. Diagnosis requires detailed history taking, whole-body imaging studies, and examination of renal function.
During follow-up periods ranging from six months to 10 years, no increase in IOP over time was found in AMD or DME patients who received intravitreal injection of an anti-VEGF agent, no matter how many injections they received.
In the SAKURA study, a greater proportion of those in the intravitreal sirolimus treatment groups than those in the active control group met the primary endpoint, a vitreous haze score of zero at Month 5 without the use of rescue therapy.
In a new study, stroke occurred in 6.6% of the ranibizumab-treated group, compared with 7.0% of the controls matched by sociodemographic factors and comorbidities and 6.7% of the controls matched by sociodemographic factors only. These differences were not statistically significant.
A retrospective review of patients with bilateral uveitic glaucoma who had filtration surgery in both eyes at different times found that the second surgically treated eye showed greater glaucomatous disc progression than the first.
A Spanish research team found an association between testing positive for antibodies to adalimumab (Humira) and a worse outcome of uveitis, but only in those who tested positive permanently. They also found that this association correlated with undetectable trough levels of Humira.
The billion-dollar combination of pegpleranib and ranibizumab failed to meet primary endpoints in studies for the treatment of age-related macular degeneration.
Most patients with severe refractory juvenile ideiopathic arthritis-associated uveitis may get complete remission after six months of treatment with tocilizumab (Actemra/Roche.)

Most Popular in Ophthalmology - Page 2

Recent Published Journal

@MDMagazine

$vacMongoViewPlus$ $vAR$